Glendon E. French III Sells 20,000 Shares of Pulmonx Co. (NASDAQ:LUNG) Stock

Pulmonx Co. (NASDAQ:LUNG) Director Glendon E. French III sold 20,000 shares of the firm’s stock in a transaction on Thursday, October 17th. The stock was sold at an average price of $6.52, for a total value of $130,400.00. Following the completion of the transaction, the director now directly owns 1,091,974 shares of the company’s stock, valued at $7,119,670.48. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Pulmonx Stock Down 4.0 %

Shares of NASDAQ:LUNG traded down $0.26 during trading on Monday, hitting $6.24. The stock had a trading volume of 150,858 shares, compared to its average volume of 406,737. Pulmonx Co. has a 12 month low of $5.46 and a 12 month high of $14.84. The company has a market capitalization of $242.21 million, a PE ratio of -4.05 and a beta of 0.64. The firm’s fifty day moving average is $7.30 and its 200 day moving average is $7.35. The company has a quick ratio of 7.92, a current ratio of 8.97 and a debt-to-equity ratio of 0.37.

Pulmonx (NASDAQ:LUNG) last announced its earnings results on Wednesday, July 31st. The company reported ($0.39) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.41) by $0.02. The firm had revenue of $20.78 million during the quarter, compared to analyst estimates of $20.23 million. Pulmonx had a negative return on equity of 50.79% and a negative net margin of 75.56%. Analysts anticipate that Pulmonx Co. will post -1.64 EPS for the current fiscal year.

Institutional Trading of Pulmonx

Several hedge funds and other institutional investors have recently made changes to their positions in LUNG. Allspring Global Investments Holdings LLC grew its stake in shares of Pulmonx by 609.7% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 8,516 shares of the company’s stock worth $79,000 after buying an additional 7,316 shares during the last quarter. Sei Investments Co. grew its stake in shares of Pulmonx by 2.5% in the 1st quarter. Sei Investments Co. now owns 72,626 shares of the company’s stock worth $673,000 after buying an additional 1,800 shares during the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. boosted its stake in Pulmonx by 6.4% during the 1st quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 989,423 shares of the company’s stock valued at $9,172,000 after purchasing an additional 59,835 shares during the last quarter. Vanguard Group Inc. boosted its stake in Pulmonx by 0.6% during the 1st quarter. Vanguard Group Inc. now owns 2,077,859 shares of the company’s stock valued at $19,262,000 after purchasing an additional 11,417 shares during the last quarter. Finally, EntryPoint Capital LLC purchased a new stake in Pulmonx during the 1st quarter valued at $102,000. Hedge funds and other institutional investors own 91.04% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts recently issued reports on LUNG shares. Wells Fargo & Company dropped their price objective on Pulmonx from $14.00 to $10.00 and set an “equal weight” rating for the company in a research note on Thursday, August 1st. Canaccord Genuity Group lifted their price objective on Pulmonx from $15.00 to $16.00 and gave the company a “buy” rating in a research note on Thursday, August 1st. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $14.83.

Pulmonx Company Profile

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.